MedTrace Logo

First-in-human Single and Multiple Dose Trial of ATR-258

NCT05409924 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2023-12-18

No results posted yet for this study

Summary

This is a single-site, randomized, double-blinded, placebo-controlled, First-in-Human trial, conducted in 3 parts.

Conditions

Interventions

DRUG

ATR-258

Single Ascending Dose

DRUG

ATR-258

Multiple Ascending Dose

DRUG

ATR-258

Repeat Dose

Sponsors & Collaborators

  • Key2Compliance

    collaborator INDUSTRY

  • CRS Clinical Research Services Mannheim GmbH

    collaborator INDUSTRY

  • Atrogi AB

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2023-10-04
Completion
2023-10-04

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05409924 on ClinicalTrials.gov